OTC Markets OTCPK - Delayed Quote USD

BeiGene, Ltd. (BEIGF)

15.95

-3.06

(-16.10%)

As of April 9 at 10:52:40 AM EDT. Market Open.

Will This Cancer Stock Buck Trump's Tariff Onslaught As It Nears Buy Point, Earnings?

BeiGene stock has formed an early-stage base with a buy point of 287.88 ahead of its first-quarter results on May 7.

Investor's Business Daily 2 hours ago

BEIGF
-16.10%
ONC
Exploring 3 High Growth Tech Stocks In The US Market

Over the last 7 days, the United States market has experienced a 1.7% drop, but it has shown resilience with a 3.6% rise over the past year and an anticipated annual earnings growth of 13%. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong potential for innovation and scalability in alignment with these positive long-term market trends.

Simply Wall St. yesterday

NBIX

BEIGF
-16.10%
ONC
BeiGene to Announce First Quarter 2025 Financial Results on May 7

SAN CARLOS, Calif., April 17, 2025--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., will report its first quarter 2025 financial results on Wednesday, May 7, 2025 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET.

Business Wire 7 days ago

BEIGF
-16.10%
ONC
BeiGene (NasdaqGS:ONC) Gains 32% In A Quarter Amid Positive EMA Opinion On TEVIMBRA

BeiGene (NasdaqGS:ONC) has climbed 32% over the past quarter, against a backdrop of significant industry challenges and broad market declines. The company's positive momentum can be attributed to the European Medicines Agency's positive opinion on TEVIMBRA, recommended for small cell lung cancer treatment, and its recent addition to the Hang Seng China Enterprises Index. These developments underscore BeiGene's expanding presence and potential in the competitive oncology market, providing a...

Simply Wall St. 19 days ago

BEIGF
-16.10%
ONC
BeiGene halts ociperlimab amid poor Phase III trial predictions

Ociperlimab is described as a humanised IgG1 monoclonal antibody with the potential to enhance T cell-mediated immune responses against cancer.

Clinical Trials Arena 21 days ago

ONC
BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program

SAN CARLOS, Calif., April 03, 2025--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the discontinuation of its clinical development program for ociperlimab (BGB-A1217), an anti-TIGIT antibody, as a potential treatment for lung cancer.

Business Wire 21 days ago

BEIGF
-16.10%
ONC
Driven Brands Holdings Among 3 Stocks Priced Below Estimated Fair Value

Amid recent market volatility, driven by concerns over new tariffs and economic data, investors are keenly observing stocks that may be undervalued in the current climate. Identifying stocks priced below their estimated fair value can offer potential opportunities for those looking to navigate these uncertain times effectively.

Simply Wall St. 24 days ago

NFG

DRVN

BEIGF
-16.10%
BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

SAN CARLOS, Calif., March 31, 2025--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion recommending approval of TEVIMBRA® (tislelizumab), in combination with etoposide and platinum chemotherapy, as a first-line treatment for adult patients with extensive-stage small cell lun

Business Wire 24 days ago

BEIGF
-16.10%
ONC
EXCLUSIVE: Indaptus Therapeutics Starts Phase 1 Combination Study of Decoy20 With BeiGene's Cancer Drug For Advanced Solid Tumors

On Tuesday, Indaptus Therapeutics, Inc. (NASDAQ:INDP) announced it advanced to a new expansion arm of its Phase 1b/2 clinical trial of Decoy20. The expansion will evaluate the combination of Decoy20 with BeiGene Ltd's (NASDAQ:ONC) PD-1 checkpoint inhibitor, tislelizumab, focusing on safety, dose optimization, and early signs of anti-tumor activity. Initial participants will first receive one week of Decoy20 monotherapy intravenously before starting the combination treatment with Decoy20 + tislel

Benzinga last month

ONC
Q4 2024 Zymeworks Inc Earnings Call

Q4 2024 Zymeworks Inc Earnings Call

Thomson Reuters StreetEvents last month

ONC
FDA Approval For BeiGene (NasdaqGS:ONC) TEVIMBRA In ESCC Shows 34 Percent Death Risk Reduction

BeiGene (NasdaqGS:ONC) experienced a significant 29% price increase over the last quarter, supported by the FDA approval of TEVIMBRA for treating esophageal squamous cell carcinoma, a key development signalling the company's progress in oncology. This approval was based on favorable results from the RATIONALE-306 trial, demonstrating improved overall survival for patients. Further bolstering investor confidence were BeiGene's improved financial reports, showcasing a rise in revenue to $3.8...

Simply Wall St. last month

BEIGF
-16.10%
ONC
FDA approves BeiGene’s Tevimbra plus chemo for oesophageal cancer

The approval results from outcomes of the placebo-controlled Phase III RATIONALE-306 study.

Pharmaceutical Technology last month

ONC
TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy

SAN MATEO, Calif., March 04, 2025--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S. Food and Drug Administration (FDA) has approved TEVIMBRA® (tislelizumab-jsgr), in combination with platinum-containing chemotherapy, for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1).

Business Wire last month

BEIGF
-16.10%
ONC
Why BeiGene, Ltd. (ONC) is Skyrocketing So Far in 2025

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where BeiGene, Ltd. (NASDAQ:ONC) stands against the other biotech stocks. No matter the market environment, you’ll always find entertainment in the biotech space. There will always be biotech […]

Insider Monkey last month

ONC
US$309 - That's What Analysts Think BeiGene, Ltd. (NASDAQ:ONC) Is Worth After These Results

It's been a good week for BeiGene, Ltd. ( NASDAQ:ONC ) shareholders, because the company has just released its latest...

Simply Wall St. last month

BEIGF
-16.10%
ONC
Is BeiGene, Ltd. (ONC) The Best Immunology Stock To Buy Now?

We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where BeiGene, Ltd. (NASDAQ:ONC) stands against other best immunology stocks to buy now. The Growing Market for Immune System Treatments Immunology is a rapidly advancing field with significant potential for growth, […]

Insider Monkey last month

ONC
BeiGene Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

BeiGene ( NASDAQ:ONC ) Full Year 2024 Results Key Financial Results Revenue: US$3.81b (up 55% from FY 2023). Net loss...

Simply Wall St. last month

BEIGF
-16.10%
ONC
BeiGene (ONC) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for BeiGene (ONC) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks last month

ONC
BeiGene Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates

SAN MATEO, Calif., February 27, 2025--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced financial results and corporate updates from the fourth quarter and full year 2024.

Business Wire last month

BEIGF
-16.10%
ONC
BeiGene to Present at Upcoming Investor Conferences

SAN MATEO, Calif., February 25, 2025--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the Company will participate in fireside chats at two upcoming investor conferences:

Business Wire last month

BEIGF
-16.10%
ONC

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

BeiGene, Ltd. (BEIGF)

Will This Cancer Stock Buck Trump's Tariff Onslaught As It Nears Buy Point, Earnings?

Exploring 3 High Growth Tech Stocks In The US Market

BeiGene to Announce First Quarter 2025 Financial Results on May 7

BeiGene (NasdaqGS:ONC) Gains 32% In A Quarter Amid Positive EMA Opinion On TEVIMBRA

BeiGene halts ociperlimab amid poor Phase III trial predictions

BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program

Driven Brands Holdings Among 3 Stocks Priced Below Estimated Fair Value

BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

EXCLUSIVE: Indaptus Therapeutics Starts Phase 1 Combination Study of Decoy20 With BeiGene's Cancer Drug For Advanced Solid Tumors

Q4 2024 Zymeworks Inc Earnings Call

FDA Approval For BeiGene (NasdaqGS:ONC) TEVIMBRA In ESCC Shows 34 Percent Death Risk Reduction

FDA approves BeiGene’s Tevimbra plus chemo for oesophageal cancer

TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy

Why BeiGene, Ltd. (ONC) is Skyrocketing So Far in 2025

US$309 - That's What Analysts Think BeiGene, Ltd. (NASDAQ:ONC) Is Worth After These Results

Is BeiGene, Ltd. (ONC) The Best Immunology Stock To Buy Now?

BeiGene Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

BeiGene (ONC) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

BeiGene Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates

BeiGene to Present at Upcoming Investor Conferences